The November 9 vote is binary: approval unlocks the Marea reverse merger and Nasdaq listing; failure triggers cash settlement risk and potential delisting. Monitor proxy solicitation results closely—support agreements cover only ~3.6% of shares. The stock price of $1.03 is far below the $4.00 minimum bid, making the reverse split essential.
Price Chart
Executive Summary
Lisata Therapeutics is holding a special annual meeting to seek stockholder approval for proposals critical to completing its reverse merger with Marea Therapeutics, which closed on September 17, 2026. The key proposals include approving the conversion of Series C Preferred Stock (which would dilute legacy stockholders to ~2.4% ownership), a reverse stock split to meet Nasdaq's $4.00 minimum bid price, and new equity plans. Failure to pass these proposals could trigger cash settlement obligations for the Series C Preferred holders and risk Nasdaq delisting.
Key Facts
- Lisata acquired Marea Therapeutics on September 17, 2026, issuing 1,793,129 common shares and 211,365.213 Series C Preferred (convertible into 211,365,213 common shares on an as-converted basis).
- A concurrent PIPE raised ~$225 million from the 150,867.995 Series C Preferred shares sold at $1,491.37 per share (~$1.49 per common share on as-converted basis).
- Post-merger, legacy Lisata stockholders own ~2.39%, Marea stockholders ~59.54%, and PIPE investors ~38.07% on a fully-diluted, as-converted basis.
- Nasdaq notified Lisata on September 25, 2026, that the Marea transaction constitutes a change of control requiring initial listing approval, including a minimum bid price of $4.00 (current price $1.03 as of October 16, 2026).
- Proposal No. 3 seeks approval to convert Series C Preferred into common stock, which would represent ~97.72% of outstanding stock on an as-converted basis.
- Proposal No. 4 seeks approval for a reverse stock split between 1:5 and 1:15 to meet Nasdaq's $4.00 minimum bid price.
- Proposals No. 5 and 6 seek approval of new 2026 Equity Incentive Plan (44,764,472 shares) and 2026 ESPP (3,730,372 shares).
- If Required Company Stockholder Matters are not approved within six months, Series C Preferred holders can demand cash settlement at fair value.
- CEO David Mazzo received total compensation of $1,147,359 in 2025 (down from $1,691,174 in 2024); no bonus was paid in 2025.
- The company reported a net loss of $17 million in 2025 (vs. $20 million in 2024).
Financial Impact
The PIPE raised ~$225 million. Legacy stockholders face massive dilution from ~97.72% to ~2.39% ownership. Failure to pass proposals could trigger cash settlement obligations for up to 385,034,614 common shares underlying Series C Preferred.
Risk Factors
- Legacy stockholders may reject the conversion proposal, triggering cash settlement obligations for Series C Preferred holders after March 17, 2027.
- Failure to approve the reverse stock split could prevent Nasdaq initial listing approval, leading to delisting.
- Massive dilution from Series C conversion reduces legacy stockholder ownership to ~2.39%.
- The company has no revenue and reported a net loss of $17 million in 2025.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001140361-26-039986 |
| Document: 0001140361-26-039986-index-headers.html | 0001140361-26-039986 |
| Document: 0001140361-26-039986-index.html | 0001140361-26-039986 |
| Document: 0001140361-26-039986.txt | 0001140361-26-039986 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEF 14A | $1.00 | awaiting T+60 | — | $1.00 (0.00%) |
Oct 14, 2026 12d ago | 8-K | $1.07 | awaiting T+60 | — | $1.00 (−6.54%) |
Sep 17, 2026 5w ago | 8-K | $1.74 | awaiting T+60 | — | $1.00 (−42.53%) |
Sep 17, 2026 5w ago | Press Release | $1.74 | awaiting T+60 | — | $1.00 (−42.53%) |
Aug 4, 2026 11w ago | 8-K | $1.14 | awaiting T+60 | — | $1.00 (+12.28%) |
Jul 24, 2026 13w ago | 8-K | $1.67 $1.00 | ▲ +40.12% | ▲ +43.41% | $1.00 (+40.12%) |
Jul 17, 2026 14w ago | 8-K | $3.60 $1.05 | ▼ −70.79% | ▼ −75.48% | $1.00 (−72.18%) |
Jun 10, 2026 19w ago | Press Release | $3.61 $1.64 | ▼ −54.57% | ▼ −61.15% | $1.00 (−72.30%) |
Jun 9, 2026 19w ago | 8-K | $3.46 $1.57 | ▲ +54.62% | ▲ +58.44% | $1.00 (+71.10%) |
Jun 1, 2026 21w ago | 8-K | $3.58 $1.74 | ▲ +51.40% | ▲ +52.63% | $1.00 (+72.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers